CA2430267A1 - Hydrazinopeptoides et leurs utilisations dans le traitement des cancers - Google Patents

Hydrazinopeptoides et leurs utilisations dans le traitement des cancers Download PDF

Info

Publication number
CA2430267A1
CA2430267A1 CA002430267A CA2430267A CA2430267A1 CA 2430267 A1 CA2430267 A1 CA 2430267A1 CA 002430267 A CA002430267 A CA 002430267A CA 2430267 A CA2430267 A CA 2430267A CA 2430267 A1 CA2430267 A1 CA 2430267A1
Authority
CA
Canada
Prior art keywords
group
compounds
formula
salt
boc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002430267A
Other languages
English (en)
French (fr)
Inventor
Yannick Bonnemains
Karine Bouget
Michele Floc'h
Philippe Le Grel
Sandrine Aubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2430267A1 publication Critical patent/CA2430267A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/20—Quaternary compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/34—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a carbon skeleton further substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA002430267A 2001-08-27 2002-08-27 Hydrazinopeptoides et leurs utilisations dans le traitement des cancers Abandoned CA2430267A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR01/11120 2001-08-27
FR0111120A FR2828884B1 (fr) 2001-08-27 2001-08-27 Hydrazinopeptoides et leurs utilisations dans le traitement des cancers
PCT/FR2002/002935 WO2003018557A1 (fr) 2001-08-27 2002-08-27 Hydrazinopeptoides et leurs utilisations dans le traitement des cancers

Publications (1)

Publication Number Publication Date
CA2430267A1 true CA2430267A1 (fr) 2003-03-06

Family

ID=8866739

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002430267A Abandoned CA2430267A1 (fr) 2001-08-27 2002-08-27 Hydrazinopeptoides et leurs utilisations dans le traitement des cancers

Country Status (6)

Country Link
US (1) US20040142851A1 (enExample)
EP (1) EP1421065A1 (enExample)
JP (1) JP2005501121A (enExample)
CA (1) CA2430267A1 (enExample)
FR (1) FR2828884B1 (enExample)
WO (1) WO2003018557A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2855971B1 (fr) * 2003-06-11 2013-01-11 Centre Nat Rech Scient Analogues peptidiques comprenant au moins un residu aza-beta3-aminoacyle, et leurs utilisations, notamment en therapie
FR2859995A1 (fr) * 2003-09-23 2005-03-25 Centre Nat Rech Scient Hydrazinopeptoides reduits et leurs utilisations dans le traitement des cancers
US8236783B2 (en) * 2006-08-15 2012-08-07 Duke University ROS-sensitive iron chelators and methods of using the same
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
CA2862580A1 (en) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to nae inhibitors
EP2776586B1 (en) 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013112601A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
US10662477B2 (en) 2012-10-01 2020-05-26 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
EP2986290A4 (en) 2013-04-19 2017-01-04 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
US20190055283A1 (en) * 2016-02-29 2019-02-21 Ohio State Innovation Foundation Aza-peptide aldehydes and ketones

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203932A (en) * 1979-03-01 1980-05-20 Gaf Corporation Phosphoryl hydrazines
SU1613508A1 (ru) * 1988-03-28 1990-12-15 Институт Химии Ан Мсср Стабилизатор электролита железнени
CA2036770C (en) * 1990-02-26 2003-09-09 Jeffrey P. Whitten Inhibitors of nitric oxide biosynthesis
WO1995018186A1 (en) * 1993-12-28 1995-07-06 Arqule Partners, L.P. Modular design and synthesis of aminimide containing molecules
DE19932796A1 (de) * 1999-07-14 2001-01-18 Merck Patent Gmbh Diacylhydrazinderivate

Also Published As

Publication number Publication date
JP2005501121A (ja) 2005-01-13
FR2828884B1 (fr) 2005-09-09
EP1421065A1 (fr) 2004-05-26
US20040142851A1 (en) 2004-07-22
WO2003018557A1 (fr) 2003-03-06
FR2828884A1 (fr) 2003-02-28

Similar Documents

Publication Publication Date Title
CN101909441B (zh) 微管蛋白抑制剂及其制备方法
JP5860397B2 (ja) トリペプチドボロン酸又はトリペプチドボロン酸エステル、その調製方法及び使用
EP0082088B1 (fr) Nouveaux dérivés d'aminoacides, et leur application thérapeutique
Liu et al. Synthesis and in vitro study of pseudo-peptide thioureas containing α-aminophosphonate moiety as potential antitumor agents
WO2005016326A2 (en) Analogs of thalidomide as potential angiogenesis inhibitors
HUE026820T2 (en) The use of Syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
CA2726907A1 (fr) Dihydro iso ca-4 et analogues : puissants cytotoxiques, inhibiteurs de la polymerisation de la tubuline
WO2003018557A1 (fr) Hydrazinopeptoides et leurs utilisations dans le traitement des cancers
CA3097622A1 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
Singh et al. Synthesis and characterization of selenium (I/II) and tellurium (IV) derivatives of amino acids
JP6468562B2 (ja) プロテアソーム阻害性化合物
WO2012085479A1 (fr) Procede de preparation de complexes carbeniques de platine
CN108218800B (zh) 1，2，3-三氮唑类氨肽酶n抑制剂及其制备方法和应用
EP3400210A2 (fr) Composés"multi-cibles"à activité inhibitrice des histone-désacétylases et de la polymérisation de la tubuline pour son utilisation dans le traitement du cancer
FR3019819A1 (fr) Composes cytotoxiques inhibiteurs de la polymerisation de la tubuline
FR2859995A1 (fr) Hydrazinopeptoides reduits et leurs utilisations dans le traitement des cancers
WO2007125196A1 (fr) Composés de type 1, 4-naphtoquinones, compositions les comprenant et utilisation de ces composés en tant qu'agents anti -cancéreux
US6630513B1 (en) Arylsulfonanilide derivates
SK94796A3 (en) Acceptability improving method of pharmaceutically effective beta-amino acids
EP2084125A1 (fr) Derives d'aminobenzocycloheptene, leurs procedes de preparation et leur utilisation en therapeutique
EP0347305B1 (fr) [(Aryl-4-pipérazinyl-1)-2 éthoxy]-3 p-cymène, les dérivés ortho, méta, para monosubstitués ou disubstitués sur le noyau phényle dudit produit, le procédé de préparation desdits dérivés, et les médicaments contenant lesdits composés comme principe actif
CA3148804A1 (fr) Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux
CA2601025C (fr) Nouveaux derives d'aminoacides phosphiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2012085475A1 (fr) Nouveaux complexes carbéniques de platine et leur utilisation comme médicaments
FR2950888A1 (fr) Modulateurs peptidiques et peptidomimetiques non competitifs specifiques de la glycoproteine p

Legal Events

Date Code Title Description
FZDE Discontinued